Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

RPS welcomes new pharmacy investment by Welsh government to tackle NHS backlog

To support NHS, clear the backlog created by the Covid-19 pandemic and help community pharmacies support more people, the Welsh government has announced an allocation of further £12.5 million funding.

Of the total amount, £10mn will be distributed across the 22 local authorities to buy equipment to help people to live independently in their own homes post hospital stay.


The remainder, £2.5mn, will be used to support community pharmacists and patients to improve access to treatment and advice for a range of common ailments.

The move is aimed at alleviating waiting times and reducing winter pressures on the NHS.

Commenting on the announcement, Elen Jones, Royal Pharmaceutical Society director for Wales said: “We are delighted that the Welsh government continue to recognize the value of pharmacists in patient care and we welcome this additional investment and support for Community Pharmacy teams across Wales.

"We fully support the approach to enhancing patient access to primary health care by further utilizing the skills and knowledge of community pharmacists. We are very pleased that these additional monies will support the flexibility and resilience of community pharmacy teams in continuing to deliver services throughout the demanding winter months.

She added that “it is vital that patients are fully informed about the range of health services available to them so they can make the right choice in accessing the right service at the right time."

More For You

Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less
Wales ranked worst for second-trimester abortion access in the UK

Each year about 175 women travel from Wales to England for care

Wales ranked worst for second-trimester abortion access in the UK

A leading healthcare charity has revealed that Wales is the worst part of the United Kingdom for allowing surgical abortions for women.

Surgical abortion is the process removing pregnancy from the womb by inducing local anaesthesia, conscious sedation or general anaesthesia.

Keep ReadingShow less
The fund offers £150 per eligible child - for up to three children per household.

The fund offers £150 per eligible child - for up to three children per household.

Charity reopens funding to ease back to school financial pressures for community pharmacists

Community pharmacists struggling with the costs of their children going back to school can apply for funding from The Leverhulme Trade Charities Trust (LTCT)

The Trust is providing up to £100,000 of support to those working in a community pharmacy or are a registered pharmacist or pharmacy technician

Keep ReadingShow less
Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less
Amandeep Doll RPS  New Director of England

Amandeep Doll

RPS announces new director of England

Amandeep Doll has been named as the new director for England at the Royal Pharmaceutical Society (RPS).

The role of Director for England drives professional leadership for the pharmacy profession in England, and leads on national policy development and advocacy across England, in partnership with the English Pharmacy Board.

Keep ReadingShow less